SEPN insider transaction filings
Septerna, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-10. Screen SEPN transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 18 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 14 legs across 9 filings by 14 insiders — 1,696,378 shares, $73,053,062 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 29.
- Largest priced transaction: sale of 746,500 shares @ $42.50 ($31,726,250) by RA CAPITAL MANAGEMENT, L.P., filed 2026-08-14.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner & RA Capital Healthcare Fund LP — Director, 10% owner & RA Capital Nexus Fund III, L.P. — Director & Kolchinsky Peter — Director, 10% owner & Shah Rajeev M. — Director, 10% owner | 2 | — | 2 legs · 1,493,000 sh · $63,452,500 | 1 |
| Third Rock Ventures V, L.P. — 10% owner & Third Rock Ventures GP V, LP — 10% owner & TRV GP V, LLC — 10% owner & Third Rock Ventures VI, L.P. — 10% owner & Third Rock Ventures GP VI, L.P. — 10% owner & TRV GP VI, LLC — 10% owner | 1 | — | 2 legs · 147,200 sh · $7,399,858 | — |
| Bhatt Elizabeth — President and COO | 2 | — | 2 legs · 29,000 sh · $1,235,974 | 6 |
| Long Daniel D. — SVP, Drug Discovery | 4 | — | 7 legs · 25,000 sh · $888,108 | 12 |
| Shaikhly Samira — Chief People Officer | 1 | — | 1 leg · 2,178 sh · $76,622 | 2 |
| Bassan Abraham — Director | 1 | — | — | 1 |
| Coulie Bernard — Director | 1 | — | — | 1 |
| Ezekowitz Alan — Director | 1 | — | — | 1 |
| Gottesdiener Keith Michael — Director | 1 | — | — | 1 |
| Patni Rajiv — Chief Medical Officer | 1 | — | — | 1 |
+3 more insiders in the window, not shown — every filing appears in the table below.
Recent Form 4 filings — Septerna, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-10 | 4 | Patni Rajiv — Chief Medical Officer | Grant/award (A): 275,000 (derivative) @ $0 | EDGAR |
| 2026-09-03 | 4 | Long Daniel D. — SVP, Drug Discovery | Option exercise (M): 3,333 @ $2.76 · Sale (S): 3,333 @ $37.83 · Option exercise (M): 3,333 (derivative) @ $0 | EDGAR |
| 2026-08-14 | 4 | Third Rock Ventures V, L.P. — 10% owner Third Rock Ventures GP V, LP — 10% owner TRV GP V, LLC — 10% owner Third Rock Ventures VI, L.P. — 10% owner Third Rock Ventures GP VI, L.P. — 10% owner TRV GP VI, LLC — 10% owner | Sale (S): 147,059 @ $50.27 · Sale (S): 141 @ $51.08 | EDGAR |
| 2026-08-14 | 4 | RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner RA Capital Healthcare Fund LP — Director, 10% owner RA Capital Nexus Fund III, L.P. — Director Kolchinsky Peter — Director, 10% owner Shah Rajeev M. — Director, 10% owner | Sale (S): 746,500 @ $42.50 · Sale (S): 746,500 @ $42.50 | EDGAR |
| 2026-08-13 | 4 | Bhatt Elizabeth — President and COO | Option exercise (M): 18,681 @ $6.81 · Option exercise (M): 6,319 @ $2.76 · Sale (S): 25,000 @ $44 · Option exercise (M): 18,681 (derivative) @ $0 · Option exercise (M): 6,319 (derivative) @ $0 | EDGAR |
| 2026-08-05 | 4 | Long Daniel D. — SVP, Drug Discovery | Option exercise (M): 1,816 @ $2.76 · Option exercise (M): 1,518 @ $2.76 · Sale (S): 1,000 @ $33.98 · Sale (S): 2,334 @ $34.68 · Option exercise (M): 1,816 (derivative) @ $0 · Option exercise (M): 1,518 (derivative) @ $0 | EDGAR |
| 2026-07-17 | 4 | Bhatt Elizabeth — President and COO | Option exercise (M): 4,000 @ $6.81 · Sale (S): 4,000 @ $33.99 · Option exercise (M): 4,000 (derivative) @ $0 | EDGAR |
| 2026-07-02 | 4 | Long Daniel D. — SVP, Drug Discovery | Option exercise (M): 3,333 @ $2.76 · Sale (S): 2,100 @ $34.10 · Sale (S): 1,233 @ $34.81 · Option exercise (M): 3,333 (derivative) @ $0 | EDGAR |
| 2026-06-30 | 4 | Shaikhly Samira — Chief People Officer | Option exercise (M): 2,178 @ $6.81 · Sale (S): 2,178 @ $35.18 · Option exercise (M): 2,178 (derivative) @ $0 | EDGAR |
| 2026-06-30 | 4 | Bassan Abraham — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-06-30 | 4 | Simson Jake — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-06-30 | 4 | Coulie Bernard — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-06-30 | 4 | Ezekowitz Alan — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-06-30 | 4 | Gottesdiener Keith Michael — Director | Grant/award (A): 11,260 (derivative) @ $0 | EDGAR |
| 2026-06-30 | 4 | Tong Jeffrey K — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-06-30 | 4 | Sharp Shalini — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-06-30 | 4 | RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner RA Capital Healthcare Fund LP — Director, 10% owner RA Capital Nexus Fund III, L.P. — Director Kolchinsky Peter — Director, 10% owner Shah Rajeev M. — Director, 10% owner | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-06-24 | 4 | Long Daniel D. — SVP, Drug Discovery | Option exercise (M): 10,529 @ $2.76 · Option exercise (M): 4,471 @ $11.70 · Sale (S): 8,000 @ $35.10 · Sale (S): 7,000 @ $35.97 · Option exercise (M): 10,529 (derivative) @ $0 · Option exercise (M): 4,471 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | Shaikhly Samira — Chief People Officer | Option exercise (M): 6,250 @ $11.70 · Sale (S): 6,250 @ $35.08 · Option exercise (M): 6,250 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | Shaikhly Samira — Chief People Officer | Option exercise (M): 4,355 @ $1.55 · Option exercise (M): 943 @ $2.76 · Option exercise (M): 637 @ $2.76 · Sale (S): 1,700 @ $27.78 · Sale (S): 1,346 @ $28.79 · Sale (S): 2,889 @ $29.66 · +3 more | EDGAR |
| 2026-05-28 | 4 | Shaikhly Samira — Chief People Officer | Option exercise (M): 11,798 @ $6.81 · Sale (S): 11,798 @ $30.06 · Option exercise (M): 11,798 (derivative) @ $0 | EDGAR |
| 2026-04-17 | 4 | Bhatt Elizabeth — President and COO | Option exercise (M): 4,000 @ $6.81 · Sale (S): 2,573 @ $23.76 · Sale (S): 1,101 @ $25.24 · Sale (S): 326 @ $25.86 · Option exercise (M): 4,000 (derivative) @ $0 | EDGAR |
| 2026-03-04 | 4 | Shaikhly Samira — Chief People Officer | Option exercise (M): 53,714 @ $1.55 · Option exercise (M): 11,638 @ $2.76 · Option exercise (M): 5,101 @ $2.76 · Sale (S): 4,090 @ $27.51 · Sale (S): 66,363 @ $28.14 · Option exercise (M): 53,714 (derivative) @ $0 · +2 more | EDGAR |
| 2026-02-20 | 4 | Bhatt Elizabeth — President and COO | Option exercise (M): 4,000 @ $6.81 · Sale (S): 2,200 @ $28.46 · Sale (S): 1,800 @ $29.58 · Option exercise (M): 4,000 (derivative) @ $0 | EDGAR |
| 2026-02-10 | 4 | Long Daniel D. — SVP, Drug Discovery | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2026-02-10 | 4 | Klein Uwe — SVP, Biological Sciences | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2026-02-10 | 4 | Shaikhly Samira — Chief People Officer | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2026-02-10 | 4 | Finer Jeffrey — Chief Executive Officer, Director | Grant/award (A): 400,000 (derivative) @ $0 | EDGAR |
| 2026-02-10 | 4 | Kim Jae B. — Chief Medical Officer | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2026-02-10 | 4 | Wilson Mark Andrew — Chief Legal Officer | Grant/award (A): 165,000 (derivative) @ $0 | EDGAR |
| 2026-02-10 | 4 | Bhatt Elizabeth — President and COO | Grant/award (A): 155,000 (derivative) @ $0 | EDGAR |
| 2026-02-10 | 4 | Labrucherie Gil M — Chief Financial Officer | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2025-11-13 | 4 | Long Daniel D. — SVP, Drug Discovery | Sale (S): 3,501 @ $18.06 | EDGAR |
| 2025-09-29 | 4 | Gottesdiener Keith Michael — Director | Grant/award (A): 33,246 (derivative) @ $0 | EDGAR |
| 2025-08-19 | 4 | Klein Uwe — SVP, Biological Sciences | Option exercise (M): 10,452 @ $2.76 · Option exercise (M): 4,935 @ $2.76 · Option exercise (M): 7,621 @ $6.81 · Option exercise (M): 10,452 (derivative) @ $0 · Option exercise (M): 4,935 (derivative) @ $0 · Option exercise (M): 7,621 (derivative) @ $0 | EDGAR |
| 2025-08-11 | 4 | Shaikhly Samira — Chief People Officer | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-08-11 | 4 | Finer Jeffrey — Chief Executive Officer, Director | Grant/award (A): 210,000 (derivative) @ $0 | EDGAR |
| 2025-08-11 | 4 | Long Daniel D. — SVP, Drug Discovery | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-08-11 | 4 | Klein Uwe — SVP, Biological Sciences | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-08-11 | 4 | Kim Jae B. — Chief Medical Officer | Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2025-08-11 | 4 | Bhatt Elizabeth — President and COO | Grant/award (A): 95,000 (derivative) @ $0 | EDGAR |
| 2025-08-11 | 4 | Labrucherie Gil M — Chief Financial Officer | Grant/award (A): 37,500 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | Bassan Abraham — Director | Grant/award (A): 16,623 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | Simson Jake — Director | Grant/award (A): 16,623 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | Coulie Bernard — Director | Grant/award (A): 16,623 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | Ezekowitz Alan — Director | Grant/award (A): 16,623 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | Tong Jeffrey K — Director | Grant/award (A): 16,623 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | Sharp Shalini — Director | Grant/award (A): 16,623 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner RA Capital Healthcare Fund LP — Director, 10% owner RA Capital Nexus Fund III, L.P. — Director Kolchinsky Peter — Director, 10% owner Shah Rajeev M. — Director, 10% owner | Grant/award (A): 16,623 (derivative) @ $0 | EDGAR |
| 2025-04-04 | 4 | Finer Jeffrey — CEO and President, Director | Option exercise (M): 50,000 @ $2.76 · Option exercise (M): 5,000 @ $2.76 · Option exercise (M): 50,000 (derivative) @ $0 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Septerna, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-25 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-30 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-13 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-09 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-02 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-12 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-08 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=SEPN returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →